ArticleClinical cancer research : an official journal of the American Association for Cancer Research2011

HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.

Tri Nguyen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.